Clinical Evidence

Artcure® is backed by multiple peer-reviewed, randomized, placebo-controlled clinical studies conducted at leading research hospitals.

76%

Average VAS pain reduction in 48h

200+

Clinical study participants

3+

Peer-reviewed publications

Lumbar Disc Herniation 2012

Dışkapı Training & Research Hospital

Lead: Assoc. Prof. Dr. Mehmet Sorar · 80 patients (40 treatment, 40 placebo)

VAS pain scores dropped from 7.85 to 3.15 within 24h and 1.86 within 48h (P<0.001). MRI showed massive contraction of herniated areas after 4 weeks.

Lumbar Disc Herniation with Radiculopathy 2017 Turkish Journal of Medical Sciences (TÜBİTAK)

Yıldırım Beyazıt University

Lead: Dr. Mahmut Uğurlu et al. · 79 clinically diagnosed patients ·

Dramatic recovery in Oswestry Disability Index and VAS values in the first month. Statistically significant difference vs. control group.

Cervical Disc Herniation 2022 Medicine Science International Medical Journal

İnönü University, Faculty of Medicine

Lead: Dr. Hüseyin Çolak et al. · 48 patients (double-blind, randomized, placebo-controlled) ·

Significant pain reduction, neuropathic symptom improvement, and functional level gains at 4th and 12th weeks vs. placebo group.

Regulatory Certifications

Artcure® meets the highest international standards for medical device safety and quality.

CE Marking

EU Medical Device Directive 93/42/EEC

Full Quality Assurance Certificate · Class IIb · Notified Body NB 1783 (TSE)

MHRA Registered

UK Medicines & Healthcare Products Regulatory Agency

Registration confirmed May 2024 · GMDN 61148

GMDN Classification

Code 61148 — Intervertebral Disc Prolapse Therapy Pack

Internationally recognized medical device nomenclature classification

ISO Compliance

Quality Management System

Manufactured under full quality assurance with systematic clinical evaluation

Frequently Asked Questions

Important information about Artcure® for patients and healthcare professionals.

Artcure® PW Diffusional Patch is a Class IIb medical device designed for the non-surgical treatment of lumbar and cervical disc herniations. It works through transdermal diffusion of a proprietary herbal formulation that promotes the natural resorption (shrinkage) of herniated disc material.
Artcure® is classified as a Class IIb medical device under EU Medical Device Directive 93/42/EEC, not a pharmaceutical medicine. It is CE marked (Notified Body NB 1783) and registered with the UK MHRA.
While Artcure® does not require a prescription in the UK, we strongly recommend that you use it under the supervision of a qualified healthcare professional.
Artcure® is indicated specifically for lumbar disc herniation and cervical disc herniation. It is not intended for other spinal conditions, general back pain without a confirmed disc herniation diagnosis, or any non-spinal musculoskeletal conditions.
A standard treatment course is 4 weeks with continuous patch application as directed. Clinical studies showed significant pain reduction (VAS scores) within 24–48 hours, with continued improvement and MRI-confirmed disc resorption over the 4-week period. Individual results may vary.
Artcure® is contraindicated in the following cases: pregnancy or breastfeeding, known allergy to herbal oils or any patch component, open wounds or skin conditions at the application site, active skin infections in the treatment area, patients under 18 years of age, and those with severe systemic conditions unless cleared by a physician. If any of these apply, do not purchase or use the product — consult your doctor instead.
The most commonly reported side effect is mild, temporary skin redness or irritation at the application site, which typically resolves on its own. In clinical studies involving 200+ participants, no serious adverse effects were reported. If you experience severe irritation, blistering, or an allergic reaction, remove the patch immediately and seek medical advice.
Yes. Artcure® has been evaluated in multiple peer-reviewed, randomized, double-blind, placebo-controlled clinical studies at leading university hospitals including Dışkapı Training & Research Hospital, Yıldırım Beyazıt University, and İnönü University Faculty of Medicine. Results have been published in indexed medical journals and demonstrate statistically significant pain reduction and functional improvement.
Artcure® may be used alongside physiotherapy and standard pain management under your physician's guidance. However, do not apply other topical treatments to the same skin area simultaneously. Always inform your healthcare provider about all treatments you are using.
We have partnered with EG Health (eghealth.co.uk) to offer Artcure® patients a £50 discount on MRI scans. This helps patients obtain the diagnostic imaging needed to confirm their disc herniation diagnosis. Simply mention Artcure® when booking your scan at EG Health.
Yes. We've partnered with Bubu Wellness Centre (bubucentre.co.uk) in London, who offer two options: In-Clinic Treatment, where you receive a professional assessment with physiotherapy or sports massage followed by Artcure® application by a qualified practitioner; or Home Application, where you purchase Artcure® at the clinic with professional guidance on correct application technique to continue treatment at home.
Due to the nature of Artcure® as a medical device, opened and used products cannot be returned for hygiene and safety reasons. Unopened products may be returned within 14 days of delivery in their original sealed packaging. Please contact us at the details provided on our Contact page to arrange a return.
No. While clinical evidence demonstrates statistically significant improvements in pain scores and disc resorption, individual results may vary. Artcure® is not a guaranteed cure. It is a treatment option that should be part of a broader care plan under medical supervision. We make no claims beyond what is supported by the published clinical data.